---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059008"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T20:46:26.464967+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Axsome Q3 product revenue $57.8M (up 244% YoY); Auvelity sales $37.7M

## Summary
- Total Q3 product revenue was $57.8M vs $16.8M in Q3 2022; Auvelity net sales $37.7M (36% sequential growth).
- Sunosi net product revenue $20.1M, up 20% YoY; total net loss of $62.2M ($1.32 per share) vs $44.8M loss in Q3 2022.
- Cash and equivalents of $416.6M at Sept 30, 2023; shares outstanding 47.3M.
- Pipeline on track: AXS-12 narcolepsy Phase 3 top-line expected Q1 2024; AXS-07 migraine NDA resubmission and AXS-14 fibromyalgia NDA submission both targeted H1 2024.
- Auvelity sales force expanding from 162 to 260 representatives; payer coverage ~70% of covered lives.

## SEC filing metadata
- accession: 0000950170-23-059008
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017023059008/0000950170-23-059008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017023059008/axsm-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059008
- JSON: https://secwatch.observer/filing/0000950170-23-059008.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059008.txt

## Key facts
- Earnings Releases
  Axsome Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue Total product revenue for the third quarter of 2023 was $57.8 million, net income Net loss for the third quarter of 2023 was $62.2 million, EPS $(1.32) per share.
  - Period: third quarter ended September 30, 2023
  - Revenue: Total product revenue for the third quarter of 2023 was $57.8 million
  - Net income: Net loss for the third quarter of 2023 was $62.2 million
  - EPS: $(1.32) per share
  - Result: reported results
  source text: Third Quarter 2023 Financial Highlights • Total product revenue for the third quarter of 2023 was $57.8 million, representing 244% year-over-year growth, and consisting of net product sales of $57.1 million and royalty revenue of $0.7 million. Total product revenue for the comparable period in 2022 was $16.8 million. • Auvelity ® net product sales were $37.7 million for the third quarter of 2023, representing a 36% sequential increase versus the second quarter of 2023. There were no Auvelity sales in the comparable 2022 period as the product was launched in October 2022. • Sunosi ® net product revenue was $20.1 million for the third quarter of 2023, representing 20% year-over-year growth, and consisting of $19.4 million in net product sales and $0.7 million in royalty revenue associated with Sunosi sales in out-licensed territories. Sunosi net product revenue for the comparable period in 2022 was $16.8 million. • Total cost of revenue was $6.5 million for the third quarter of 2023. Tot
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017023059008/0000950170-23-059008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.